The Coagulation Cascade and its Therapeutic Modulation

  • Lieze Thielemans
  • Moghees Hanif
  • James CrawleyEmail author
Part of the Learning Materials in Biosciences book series (LMB)


This chapter will provide a comprehensive overview of both primary and secondary haemostasis at a gross and molecular level, in addition to examining the relevant signalling and cellular mediators of these dual processes. We will then discuss three key regulatory mechanisms, whilst simultaneously exploring the clinical relevance of both the aforementioned mechanisms and the aberrance of coagulation.


  1. 1.
    Versteeg HH et al (2013) New fundamentals in hemostasis. Physiol Rev 93:327. Scholar
  2. 2.
    Broos K et al (2011) Platelets at work in primary hemostasis. Blood Rev 25(4):155–167. Scholar
  3. 3.
    Peyvandi F et al (2011) Role of von Willebrand factor in the haemostasis. Blood Transfus 9(Suppl 2):s3–s8. Scholar
  4. 4.
    Gale AJ (2011) Current understanding of hemostasis. Toxicol Pathol 39(1):273–280. Scholar
  5. 5.
    Seong-Hoon Y et al (2016) Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int 2016:1. Scholar
  6. 6.
    Blair P et al (2009) Platelet a-granules: basic biology and clinical correlates. Blood Rev 23(4):177–189. Scholar
  7. 7.
    Hanby HA et al (2017) Platelet dense granules begin to selectively accumulate mepacrine during proplatelet formation. Blood Adv 1(19):1478–1490. Scholar
  8. 8.
    Behan MWH, Storey RF (2004) Antiplatelet therapy in cardiovascular disease. Postgrad Med J 80:155–164. Scholar
  9. 9.
    Bhatt DL, Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2(1):15–29. Scholar
  10. 10.
    Savi P et al (1998) Clopidogrel: a review of its mechanism of action. Platelets 9(3–4):251–255. Scholar
  11. 11.
    Chatterjee S et al (2013) PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis 35(1):1–9. Scholar
  12. 12.
    Horiuchi H (2006) Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to problems. Ann Med 38(3):162–172. Scholar
  13. 13.
    Wang TH et al (2006) Aspiring and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27(6):647–654. Scholar
  14. 14.
    Pozzi N et al (2013) Autoactivation of thrombin precursors. J Biol Chem 288(16):11601–11610. Scholar
  15. 15.
    Lenting PJ et al (1998) The life cycle of coagulation factor VIII in view of its structure and function. Blood 92:3983–3996CrossRefGoogle Scholar
  16. 16.
    Geddings JE (2014) New players in haemostasis and thrombosis. Thromb Haemost 111(4):570–574. Scholar
  17. 17.
    Crawley JTB, Lane DA (2008) The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28(2):233–242. Scholar
  18. 18.
    Wood et al (2014) Biology of tissue factor pathway inhibitor. Blood 123(19):2934–2943. Scholar
  19. 19.
    Castoldi E, Hackeng TM (2008) Regulation of coagulation by protein S. Curr Opin Haematol 15(5):529–536. Scholar
  20. 20.
    Kalafatis M, Rand MD, Mann KG (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269(50):31869–31880PubMedGoogle Scholar
  21. 21.
    Rosenberg RD, Damus PS (1973) The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248(18):6490–6505PubMedGoogle Scholar
  22. 22.
    Lim GB (2015) Anticoagulants. Nat Rev Cardiol.
  23. 23.
    Hirsh J et al (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107:1692–1711CrossRefGoogle Scholar
  24. 24.
    Hirsh J et al (2001) Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest J 119(1):64S–94S. doi: 0.1378/chest.119.1_suppl.64SCrossRefGoogle Scholar
  25. 25.
    Basu D et al (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. NEJM 287:324–327. Scholar
  26. 26.
    Salzman EW et al (1975) Management of heparin therapy – controlled prospective trial. NEJM 292:1046–1050.
  27. 27.
    Pollack CV Jr (2016) Coagulation assessment with the new generation of oral anticoagulants. BMJ 33(6):423–430Google Scholar
  28. 28.
    Wilson MR, Docherty KF, Gardner RS (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber Drug Rev 27(8):15. Scholar
  29. 29.
    Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115(1):15–20. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Lieze Thielemans
    • 1
  • Moghees Hanif
    • 1
    • 2
  • James Crawley
    • 3
    Email author
  1. 1.Imperial College LondonLondonUK
  2. 2.Queen Mary University of LondonLondonUK
  3. 3.Centre for Haematology, Imperial College LondonLondonUK

Personalised recommendations